Micro-RNA 150-5p predicts overt heart failure in patients with univentricular hearts

Abstract

BackgroundIn patients with left heart failure, micro-RNAs (miRNAs) have been shown to be of diagnostic and prognostic value. The present study aims to identify those miRNAs in patients with univentricular heart (UVH) disease that may be associated with overt heart failure.MethodsA large panel of human miRNA arrays were used to determine miRNA expression profiles in the blood of 48 UVH patients and 32 healthy controls. For further selection, the most abundantly expressed miRNA arrays were related to clinical measures of heart failure and selected miRNAs validated by polymerase chain reaction were used for the prediction of overt heart failure and all-cause mortality.ResultsAccording to microarray analysis, 50 miRNAs were found to be significantly abundant in UVH patients of which miR-150-5p was best related to heart failure parameters. According to ROC analysis, NT-proBNP levels (AUC 0.940, 95% CI 0.873–1.000; p = 0.001), miR-150-5p (AUC 0.905, 95% CI 0.779–1.000; p = 0.001) and a higher NYHA class ≥ III (AUC 0.893, 95% CI 0.713–1.000; p = 0.002) were the 3 most significant predictors of overt heart failure. Using a combined biomarker model, AUC increased to 0.980 indicating an additive value of miR-150-5p. Moreover, in the multivariate analysis, a higher NYHA class ≥ III (p = 0.005) and miR-150-5p (p = 0.006) turned out to be independent predictors of overt heart failure.ConclusionIn patients with UVH, miR-150-5p is an independent predictor of overt heart failure and thus may be used in the risk assessment of these patients.

Insights from circulating microRNAs in cardiovascular entities in turner syndrome patients

“…The relative abundance level for each miRNA was calculated using the 2 −ΔΔCT equation [23]. RNU6B small nuclear RNA (snRNA) was used an endogenous reference control for normalization purpose as previously described [12,13,22,[24][25][26][27] and because of its minimum abundance variance between the TS patients and HVs as observed by DataAssist™Software (Applied Biosystems). Correlations were computed using Spearman's regression coefficient and the difference between the groups was analyzed using a Mann-Whitney-U test using GraphPad Prism 7.0.…”

MicroRNA-29b/c-3p Indicate Advanced Liver Fibrosis/Cirrhosis in Univentricular Heart Patients With and Without Fontan Palliation

“…Additionally, ultrasonographic parameters of liver congestion such as the diameter of the inferior caval vein (IVC) at deep inspiration and expiration were measured to calculate the collapsibility index ( 20 ). Clinical characteristics of the patient cohort and UVH-specific data have already been presented in a previous study ( 21 ). Patients' specific liver parameters are illustrated in Table 1 .…”

“…The miRNA abundance profile from the 48 patients with UVH and 32 age- and gender-matched healthy controls was obtained from our previously generated and uploaded raw data to the NCBI GEO database (Accession ID: GSE136547 ) using SurePrint™ 8X60K Human v21 miRNA platforms (Agilent Technologies) ( 21 ). These platforms contain probes for the detection of 2,549 human miRNAs.…”

“…Real-time quantitative PCR (RT-qPCR) validation analysis was performed using the StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, CA, United States) and the mi Script PCR System (Qiagen) as previously described ( 24 ). For the validation step, we used the same samples that were used for the microarray analysis (48 UVH patients and 32 healthy controls) ( 21 ). Fifteen miRNAs (miR-101-3p, miR-144-5p, miR-18a-5p, miR-15a-5p, miR-17-3p, miR-96-5p, miR-18b-5p, miR-140-5p, miR-148a-3p, miR-29b-3p, miR-29c-3p, miR-210-3p, miR-125a-5p, miR-150-5p, and miR-324-3p) were chosen for RT-qPCR validation based on the significant abundance changes on the microarray analysis.…”

Determinants of soluble angiotensin-converting enzyme 2 concentrations in adult patients with complex congenital heart disease

“…In our outpatient clinic for adults with CHD, several prospective studies for the evaluation of different biomarkers in serum as well as micro-RNA signatures in whole blood had been performed in the past [23][24][25]. To assess sACE2 concentrations, existing serum samples of these patients frozen at -80° C representing the pre-COVID-19 era were used for analysis.…”